Combination of a BTK inhibitor and an MDM2 inhibitor for cancer treatment

Therapeutic methods and pharmaceutical compositions for treating a cancer, including a B cell hematological malignancy selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL),...

Full description

Saved in:
Bibliographic Details
Main Author ROTHBAUM, Wayne
Format Patent
LanguageEnglish
Published 09.06.2022
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Therapeutic methods and pharmaceutical compositions for treating a cancer, including a B cell hematological malignancy selected from the group consisting of chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), non-Hodgkin's lymphoma (NHL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Hodgkin's lymphoma, B cell acute lymphoblastic leukemia (B-ALL), Burkitt's lymphoma, and Waldenström's macroglobulinemia (WM).
Bibliography:Application Number: AU20200383537